Stocktoria

ArriVent BioPharma, Inc. AVBP

Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2024-01-26

ArriVent BioPharma, Inc. statistics & valuation

Market cap$1.6B
P / B5.2×
Return on equity-54.1%
Return on capital-57.8%

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Gross margin (%)
202320242025
Operating margin (%)
202320242025
Return on equity (%)
-31.20% -54.10% 202320242025
Shares outstanding
2.7M 33.7M 42.5M 202320242025
Net debt ($)
202320242025
Share buybacks ($)
202320242025
Return on assets (%)
-42.50% -29.30% -49.90% 202320242025
Free cash flow margin (%)
202320242025
Debt / equity (×)
202320242025
EPS ($)
-$32.38 -$2.56 -$4.32 202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023
Return on assets-49.9%-29.3%-42.5%
Return on equity-54.1%-31.2%45.3%
Current ratio12.8313.1413.76

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.